IMMUNE THROMBOCYTOPENIA
Clinical trials for IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy shows promise for rare bleeding disorder
Disease control OngoingThis study tests whether adding diammonium glycyrrhizinate (a liver-protecting compound) to high-dose dexamethasone works better than dexamethasone alone for adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Shandong University • Aim: Disease control
Last updated May 26, 2026 11:24 UTC
-
New pill shows promise for rare bleeding disorder in phase 3 trial
Disease control OngoingThis study tested an oral drug called rilzabrutinib in 232 adults and adolescents with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants received either the drug or a placebo twice dail…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Principia Biopharma, a Sanofi Company • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
ITP drug study halted before it began
Disease control TerminatedThis study was designed to test an experimental drug called HMPL-523 in adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding problems. The goal was to see if the drug is safe and can raise platelet counts. However, th…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated May 18, 2026 12:10 UTC
-
Ongoing access to experimental ITP drug for japanese patients
Disease control OngoingThis study offers continued treatment with the oral drug rilzabrutinib to adults with chronic immune thrombocytopenia (ITP) who have already completed a long-term extension study in Japan. Only 4 participants who showed meaningful benefit and acceptable safety are eligible. The m…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Apr 24, 2026 16:06 UTC